Details of the Drug
General Information of Drug (ID: DMT2EJP)
| Drug Name |
Podofilox
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
podophyllotoxin; 518-28-5; Condylox; Condyline; Wartec; Podophyllotoxin 7; Podophyllinic acid lactone; Warticon; (-)-Podophyllotoxin; Podofilox [USAN]; CCRIS 565; UNII-L36H50F353; Podophyllotoxin, 95%; HSDB 7238; NSC24818; CHEMBL61; EINECS 208-250-4; NSC 24818; (5R,5aR,8aR,9R)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one; MLS000069495; AI3-50456; CHEBI:50305; Podofilox (USAN); L36H50F353; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one,; Podophyllotoxin
|
||||||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||||||
| Affected Organisms |
Condyloma acuminatum
|
||||||||||||||||||||||||||
| ATC Code | |||||||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 414.4 | |||||||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||||||||||
| ADMET Property |
|
||||||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||||||||||
| Drug Pharmacogenomic Perturbation (DPP)NEW | Click to Jump to the Detailed DPP Information of This Drug | ||||||||||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||||||||||
| Combinatorial Drugs (CBD) | Click to Jump to the Detailed CBD Information of This Drug | ||||||||||||||||||||||||||
| Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug-Metabolizing Enzyme (DME) |
|
|||||||||||||||||||||||||
![]() Drug Off-Target (DOT) |
|
|||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
| 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
|---|---|---|---|---|---|
| 2 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
| 3 | Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39. | ||||
| 4 | Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8. | ||||
| 5 | Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays. J Med Chem. 2011 Oct 27;54(20):7138-49. doi: 10.1021/jm200737s. Epub 2011 Sep 29. | ||||




